[7]Veitch Z, Ribnikar D, Tilley D, et al. No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. Br J Cancer. 2022 Apr;126(6):881-888. ...
Real-world analysis of inetetamab-based therapy for the treatment of HER2-positive advanced breast cancer 含伊尼妥单抗方案用于治疗HER2阳性晚期乳腺癌的真实世界研究 研究背景 伊尼妥单抗是Fc段改构的创新型抗HER2单克隆抗体。此前已经证实其在HER2阳性晚期乳腺癌中具有良好的疗效的安全性。本研究探索了含伊尼妥...
This review describes the therapeutic landscape for HER2-positive advanced breast cancer (ABC) and evaluates its benefits and risks in the clinical setting.doi:10.2147/OTT.S335934P. MandóF. WaisbergR. PasquinelliS. RiveroA. OstinelliF. Perazzo...
[1]Mandó P, Waisberg F, Pasquinelli R, Rivero S, Ostinelli A, Perazzo F. HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks. Onco Targets Ther. 2023 Feb 19;16:115-132. doi: 10.2147/OTT.S335934. PMID: 36844609; PMCID:...
[10]Nakada T,Sugihara K,Jikoh T,et al.The Latest Research and Development into the Antibody-Drug Conjugate,[fam-]Trastuzumab Deruxtecan(DS-8201a),for HER2 Cancer Therapy.Chem Pharm Bull(Tokyo).2019;67(3):173-185. [11]Ogitani Y,Aida T,Hagihara K,et al.DS-8201a,A Novel HER2-Target...
《2022 ASCO Educational Book》发表的一篇报道“Systemic Therapy for HER2-Positive Metastatic Breast Cancer:Moving Into a New Era”指出,当前HER2阳性转移性乳腺癌(MBC)的治疗目标是根据疾病和患者的特征量身定制治疗强度,以提高治愈率,同时将过度治疗风险降到最低,这为制定HER2阳性MBC的治疗策略提示了重要方向。
[3]Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(12):1183-1192. ...
[1] GS2-12 AFT-38 PATINA: a Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib +Anti-HER2 Therapy +Endocrine Therapy vs. Anti-HER2 Therapy +Endocrine Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER-Positive Metastatic Breast. ...
Trastuzumab plus chemotherapy is the standard-of-care first-line therapy for patients with HER2-positive gastric cancer, although trials involving pertuzumab, lapatinib and T-DM1 have failed to reveal any improvements in outcomes. HER2-targeted therapies are being tested in other tumour types, includin...
OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks Pablo Mandó 1, Federico Waisberg 2, Rosario Pasquinelli1, Sergio Rivero2, Alexis Ostinelli2, Florencia Perazzo1 1...